Abstract
Normocalcemic primary hyperparathyroidism is an entity on which several issues about its clinical management remains unclear. This is reflected in the main current guidelines, where there are no evidence-based specific recommendations. Through an exhaustive review of current literature, a clinical management algorithm for these patients is proposed. We consider the diagnosis criteria, the differential diagnosis, the clinical manifestations, and the treatment indications. When indicated, we also review the preoperative locations techniques and the surgical approach. Finally, when surgical treatment is not indicated, the patient is not a candidate to surgery or refuse surgical management, we review the medical treatment options and the follow-up schemes.
Similar content being viewed by others
References
J.P. Bilezikian, A.A. Khan, J.T. Potts, Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 94, 335–339 (2009). https://doi.org/10.1210/jc.2008-1763
N.E. Cusano, S.J. Silverberg, J.P. Bilezikian, Normocalcemic primary hyperparathyroidism. J. Clin. Densitom. 16, 33–39 (2013). https://doi.org/10.1016/j.jocd.2012.12.001
J.P. Bilezikian, M.L. Brandi, R. Eastell, S.J. Silverberg, R. Udelsman, C. Marcocci, J.T. Potts, Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the fourth international workshop. J. Clin. Endocrinol. Metab. 99, 3561–3569 (2014). https://doi.org/10.1210/jc.2014-1413
S.M. Wilhelm, T.S. Wang, D.T. Ruan, J.A. Lee, S.L. Asa, Q.Y. Duh, G.M. Doherty, M.F. Herrera, J.L. Pasieka, N.D. Perrier, S.J. Silverberg, C.C. Solórzano, C. Sturgeon, M.E. Tublin, R. Udelsman, S.E. Carty, The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg. 151, 959–968 (2016). https://doi.org/10.1001/jamasurg.2016.2310
R. Eastell, M.L. Brandi, A.G. Costa, P. D’Amour, D.M. Shoback, R. Thakker, V: Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J. Clin. Endocrinol. Metab. 99, 3570–3579 (2014). https://doi.org/10.1210/jc.2014-1414
M. Schini, R.M. Jacques, E. Oakes, N.F.A. Peel, J.S. Walsh, R. Eastell, Normocalcemic hyperparathyroidism: Study of its prevalence and natural history. J. Clin. Endocrinol. Metab. 105, E1171–E1186 (2020). https://doi.org/10.1210/clinem/dgaa084
J.F. Aloia, M. Feuerman, J.K. Yeh, Reference range for serum parathyroid hormone. Endocr. Pract. 12, 137–144 (2006). https://doi.org/10.4158/EP.12.2.137
C.-J.L. Farrell, L. Nguyen, A.C. Carter, Parathyroid hormone: data mining for age-related reference intervals in adults. Clin. Endocrinol. (Oxf.). 88, 311–317 (2018). https://doi.org/10.1111/cen.13486
J.A. Delgado, J.M. Bauça, M.I. Pastor, A. Barceló, Use of data mining in the establishment of age-adjusted reference intervals for parathyroid hormone. Clin. Chim. Acta 508, 217–220 (2020). https://doi.org/10.1016/j.cca.2020.05.030
N.B. Dawood, K.L. Yan, A. Shieh, M.J. Livhits, M.W. Yeh, A.M. Leung, Normocalcaemic primary hyperparathyroidism: An update on diagnostic and management challenges. Clin. Endocrinol. (Oxf.). 93, 519–527 (2020). https://doi.org/10.1111/cen.14315
J. Gómez-Ramírez, A. Gómez-Valdazo, P. Luengo, B. Porrero, I. Osorio, S. Rivas, Comparative prospective study on the presentation of normocalcemic primary hyperparathyroidism. Is it more aggressive than the hypercalcemic form? Am. J. Surg. 219, 150–153 (2020). https://doi.org/10.1016/j.amjsurg.2019.10.032
L.M. Calvi, D.A. Bushinsky, When is it appropriate to order an ionized calcium? J. Am. Soc. Nephrol. 19, 1257–1260 (2008). https://doi.org/10.1681/ASN.2007121327
S. Corbetta, Normocalcemic Hyperparathyroidism. Front. Horm. Res. 51, 23–39 (2019). https://doi.org/10.1159/000491036
G. Zavatta, B.L. Clarke, Normocalcemic Hyperparathyroidism: A Heterogeneous Disorder Often Misdiagnosed? JBMR 4, e10391 (2020). https://doi.org/10.1002/jbm4.10391
A. Giustina, R. Bouillon, N. Binkley, C. Sempos, R.A. Adler, J. Bollerslev, B. Dawson-Hughes, P.R. Ebeling, D. Feldman, A. Heijboer, G. Jones, C.S. Kovacs, M. Lazaretti-Castro, P. Lips, C. Marcocci, S. Minisola, N. Napoli, R. Rizzoli, R. Scragg, J.H. White, A.M. Formenti, J.P. Bilezikian, C. Labrador, Controversies in Vitamin D: A Statement From the Third International Conference. JBMR . 4, e10417 (2020). https://doi.org/10.1002/jbm4.10417
C. Cipriani, J. Pepe, L. Colangelo, S. Minisola, Vitamin D and Secondary Hyperparathyroid States. Front. Horm. Res. 50, 138–148 (2018). https://doi.org/10.1159/000486077
A. Palermo, A.M. Naciu, G. Tabacco, S. Falcone, A. Santonati, D. Maggi, L.D.’ Onofrio, S.I. Briganti, D. Castellitto, A. Casini, C. Pedone, D. Lelli, A. Fabbri, J.P. Bilezikian, N. Napoli, P. Pozzilli, S. Manfrini, R. Cesareo, Clinical, biochemical, and radiological profile of normocalcemic primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 105, 2609–2616 (2020). https://doi.org/10.1210/clinem/dgaa174
B.C. Silva, N.E. Cusano, J.P. Bilezikian, Primary hyperparathyroidism. Best Pract. Res. Clin. Endocrinol. Metab. 101247 (2018). https://doi.org/10.1016/j.beem.2018.09.013
X. Wang, L. Meng, C. Su, S.A. Shapses, Low free (but not total) 25-hydroxyvitamin D levels in subjects with normocalcemic hyperparathyroidism. Endocr. Pract. 26, 174–178 (2020). https://doi.org/10.4158/EP-2019-0325
N.E. Cusano, C. Cipriani, J.P. Bilezikian, Management of normocalcemic primary hyperparathyroidism. Best. Pract. Res. Clin. Endocrinol. Metab. 32, 837–845 (2018). https://doi.org/10.1016/j.beem.2018.09.009
J. Gómez-Ramírez, R. Mihai, Normocalcaemic primary hyperparathyroidism: a diagnostic and therapeutic algorithm. Langenbeck’s Arch. Surg. 402, 1103–1108 (2017). https://doi.org/10.1007/s00423-017-1617-2
C. Eller-Vainicher, E. Cairoli, V.V. Zhukouskaya, V. Morelli, S. Palmieri, A. Scillitani, P. Beck-Peccoz, I. Chiodini, Prevalence of subclinical contributors to low bone mineral density and/or fragility fracture. Eur. J. Endocrinol. 169, 225–237 (2013). https://doi.org/10.1530/EJE-13-0102
G. Martínez Díaz-Guerra, E. Jódar Gimeno, R. Reyes García, J.M. Gómez Sáez, M. Muñoz-Torres, Normocalcemic primary hyperparathyroidism: recommendations for management and follow-up. Endocrinol. Nutr. 60, 456–.e1–6 (2013). https://doi.org/10.1016/j.endonu.2013.01.015
B.H. Eisner, J. Ahn, M.L. Stoller, Differentiating primary from secondary hyperparathyroidism in stone patients: the “thiazide challenge”. J. Endourol. 23, 191–192 (2009). https://doi.org/10.1089/end.2008.0567
M.L. Griebeler, A.E. Kearns, E. Ryu, P. Thapa, M.A. Hathcock, L.J. Melton, R.A. Wermers, Thiazide-associated hypercalcemia: incidence and association with primary hyperparathyroidism over two decades. J. Clin. Endocrinol. Metab. 101, 1166–1173 (2016). https://doi.org/10.1210/jc.2015-3964
G. Mantovani, M. Bastepe, Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nat. Rev. Endocrinol. 47, 41. https://doi.org/10.1038/s41574-018-0042-0
D.A. Anastasilakis, P. Makras, S.A. Polyzos, A.D. Anastasilakis, Asymptomatic and normocalcemic hyperparathyroidism, the silent attack: a combo-endocrinology overview. Hormones 18, 65–70 (2019). https://doi.org/10.1007/s42000-018-0069-6
M.M. Tuna, M. Çalışkan, M. Ünal, T. Demirci, B.A. Doğan, K. Küçükler, M. Özbek, D. Berker, T. Delibaşı, S. Güler, Normocalcemic hyperparathyroidism is associated with complications similar to those of hypercalcemic hyperparathyroidism. J. Bone Miner. Metab. 34, 331–335 (2016). https://doi.org/10.1007/s00774-015-0673-3
E. Traini, R. Bellantone, S.E. Tempera, S. Russo, C. De Crea, C.P. Lombardi, M. Raffaelli, Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism? Langenbeck’s Arch. Surg. 403, 317–323 (2018). https://doi.org/10.1007/s00423-018-1659-0
C. Berger, O. Almohareb, L. Langsetmo, D.A. Hanley, C.S. Kovacs, R.G. Josse, J.D. Adachi, J.C. Prior, T. Towheed, K.S. Davison, S.M. Kaiser, J.P. Brown, D. Goltzman, Characteristics of hyperparathyroid states in the Canadian multicentre osteoporosis study (CaMos) and relationship to skeletal markers. Clin. Endocrinol. (Oxf.). 82, 359–368 (2015). https://doi.org/10.1111/cen.12569
L. Rejnmark, H. Ejlsmark-Svensson, Effects of PTH and PTH hypersecretion on bone: a clinical perspective. Curr. Osteoporos. Rep. 18, 103–114 (2020). https://doi.org/10.1007/s11914-020-00574-7
A.M. Formenti, F. Tecilazich, R. Giubbini, A. Giustina, Risk of vertebral fractures in hypoparathyroidism. Rev. Endocr. Metab. Disord. 20, 295–302 (2019). https://doi.org/10.1007/s11154-019-09507-x
A.M. Naciu, G. Tabacco, S. Falcone, G.G. Incognito, I. Chiodini, D. Maggi, C. Pedone, D. Lelli, J.P. Bilezikian, N. Napoli, S. Manfrini, R. Cesareo, A. Palermo, Bone quality, as measured by trabecular bone score in normocalcaemic primary hyperparathyroidism. Endocr. Pract. (2021). https://doi.org/10.1016/j.eprac.2021.04.884
G. Díaz-Soto, D. de Luis Román, O.I. Jauregui, L. Briongo, E. Romero, J.L. Pérez-Castrillón, Trabecular bone score in patients with normocalcemic hyperparathyroidism. Endocr. Pract. 22, 703–707 (2016). https://doi.org/10.4158/EP151055.OR
G.B. Cansu, N. Yilmaz, S. Özdem, M.K. Balci, G. Süleymanlar, C. Arici, A. Boz, R. Sari, H.A. Altunbaş, Parathyroidectomy in asymptomatic primary hyperparathyroidism reduces carotid intima-media thickness and arterial stiffness. Clin. Endocrinol. (Oxf.). 84, 39–47 (2016). https://doi.org/10.1111/cen.12952
A.J. van Ballegooijen, I. Reinders, M. Visser, I.A. Brouwer, Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am. Heart J. 165, 655–664 (2013). https://doi.org/10.1016/j.ahj.2013.02.014. 664.e1–5
G. Chen, Y. Xue, Q. Zhang, T. Xue, J. Yao, H. Huang, J. Liang, L. Li, W. Lin, L. Lin, L. Shi, L. Cai, J. Wen, Is normocalcemic primary hyperparathyroidism harmful or harmless? J. Clin. Endocrinol. Metab. 100, 2420–2424 (2015). https://doi.org/10.1210/jc.2014-4432
F.Y. Ozturk, S. Erol, M.M. Canat, S. Karatas, I. Kuzu, S.D. Cakir, Y. Altuntas, Patients with normocalcemic primary hyperparathyroidism may have similar metabolic profile as hypercalcemic patients. Endocr. J. 63, 111–118 (2016). https://doi.org/10.1507/endocrj.EJ15-0392
S. Beysel, M. Caliskan, M. Kizilgul, M. Apaydin, S. Kan, M. Ozbek, E. Cakal, Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism. BMC Cardiovasc. Disord. 19, 1–8 (2019). https://doi.org/10.1186/s12872-019-1093-4
O. Koubaity, D. Mandry, P.L. Nguyen-Thi, F. Bihain, C. Nomine-Criqui, L. Demarquet, V. Croise-Laurent, L. Brunaud, Coronary artery disease is more severe in patients with primary hyperparathyroidism. Surgery 167, 149–154 (2020). https://doi.org/10.1016/j.surg.2019.05.094
S. Temizkan, O. Kocak, K. Aydin, A. Ozderya, G. Arslan, N. Yucel, M. Sargin, Normocalcemic hyperparathyroidism and insulin resistance. Endocr. Pract. 21, 23–29 (2015). https://doi.org/10.4158/EP14195.OR
P.N. Mesquita, A.P.D.L. Leite, S. Crisóstomo, C. das, E.V. Filho, L. Da Cunha Xavier, F. Bandeira, Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism. Vasc. Health Risk Manag 13, 225–229 (2017). https://doi.org/10.2147/VHRM.S128084
L.S. Bislev, L. Langagergaard Rødbro, T. Sikjær, L. Rejnmark, Effects of elevated parathyroid hormone levels on muscle health, postural stability and quality of life in vitamin D-insufficient healthy women: a cross-sectional study. Calcif. Tissue Int. 105, 642–650 (2019). https://doi.org/10.1007/s00223-019-00612-2
L. Voss, M. Nóbrega, L. Bandeira, L. Griz, P.A.S. Rocha-Filho, F. Bandeira, Impaired physical function and evaluation of quality of life in normocalcemic and hypercalcemic primary hyperparathyroidism. Bone 141, 115583 (2020). https://doi.org/10.1016/j.bone.2020.115583
H. Lowe, D.J. McMahon, M.R. Rubin, J.P. Bilezikian, S.J. Silverberg, Normocalcemic primary hyperparathyroidism: Further characterization of a new clinical phenotype. J. Clin. Endocrinol. Metab. 92, 3001–3005 (2007). https://doi.org/10.1210/jc.2006-2802
H. Šiprová, Z. Fryšák, M. Souček, Primary hyperparathyroidism, with a focus on management of the normocalcemic form: to treat or not to treat? Endocr. Pract. 22, 294–301 (2016). https://doi.org/10.4158/EP15704.OR
H. Yan, N. Calcatera, T.A. Moo-Young, R.A. Prinz, D.J. Winchester, Degree of hypercalcemia correlates with parathyroidectomy but not with symptoms. Am. J. Surg. 217, 437–440 (2019). https://doi.org/10.1016/j.amjsurg.2018.09.010
J.Y. Lim, M.C. Herman, L. Bubis, I. Epelboym, J.D. Allendorf, J.A. Chabot, J.A. Lee, J.H. Kuo, Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism. Surgery 161, 70–77 (2017). https://doi.org/10.1016/j.surg.2016.08.054
G. Trinh, E. Rettig, S.I. Noureldine, J.O. Russell, N. Agrawal, A. Mathur, J.D. Prescott, M.A. Zeiger, R.P. Tufano, Surgical management of normocalcemic primary hyperparathyroidism and the impact of intraoperative parathyroid hormone testing on outcome. Otolaryngol. Head. Neck Surg. 159, 630–637 (2018). https://doi.org/10.1177/0194599818793879
A. Kiriakopoulos, A. Petralias, D. Linos, Classic primary hyperparathyroidism versus normocalcemic and normohormonal variants: do they really differ? World J. Surg. 42, 992–997 (2018). https://doi.org/10.1007/s00268-018-4512-2
C.E. Graves, C.M. McManus, J.A. Chabot, J.A. Lee, J.H. Kuo, Biochemical profile affects IOPTH kinetics and cure rate in primary hyperparathyroidism. World J. Surg. 44, 488–495 (2020). https://doi.org/10.1007/s00268-019-05157-x
F. Tassone, A. Guarnieri, E. Castellano, C. Baffoni, R. Attanasio, G. Borretta, Parathyroidectomy halts the deterioration of renal function in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 100, 3069–3073 (2015). https://doi.org/10.1210/jc.2015-2132
K. Lundstam, A. Heck, K. Godang, C. Mollerup, M. Baranowski, Y. Pernow, T. Aas, O. Hessman, T. Rosén, J. Nordenström, S. Jansson, M. Hellström, J. Bollerslev, Effect of surgery versus observation: skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH Study). J. Bone Miner. Res. 32, 1907–1914 (2017). https://doi.org/10.1002/jbmr.3177
S.P. Cheng, J.J. Lee, T.P. Liu, P.S. Yang, S.C. Liu, Y.C. Hsu, C.L. Liu, Quality of life after surgery or surveillance for asymptomatic primary hyperparathyroidism: a meta-analysis of randomized controlled trials. Med. (Baltim.) 94, e931 (2015). https://doi.org/10.1097/MD.0000000000000931
S. Sho, E.J. Kuo, A.C. Chen, N. Li, M.W. Yeh, M.J. Livhits, Biochemical and skeletal outcomes of parathyroidectomy for normocalcemic (incipient) primary hyperparathyroidism. Ann. Surg. Oncol. 26, 539–546 (2019). https://doi.org/10.1245/s10434-018-6998-0
D. Lee, M.D. Walker, H.Y. Chen, J.A. Chabot, J.A. Lee, J.H. Kuo, Bone mineral density changes after parathyroidectomy are dependent on biochemical profile. Surgery 165, 107–113 (2019). https://doi.org/10.1016/j.surg.2018.04.065
J. Pepe, C. Cipriani, C. Sonato, O. Raimo, F. Biamonte, S. Minisola, Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur. J. Endocrinol. 177, R297–R308 (2017). https://doi.org/10.1530/EJE-17-0485
C. Blanchard, M. Mathonnet, F. Sebag, C. Caillard, C. Kubis, D. Drui, E. van Nuvel, C. Ansquer, J.F. Henry, D. Masson, F. Kraeber-Bodéré, J.B. Hardouin, R. Zarnegar, A. Hamy, E. Mirallié, Quality of life is modestly improved in older patients with mild primary hyperparathyroidism postoperatively: results of a prospective multicenter study. Ann. Surg. Oncol. 21, 3534–3540 (2014). https://doi.org/10.1245/s10434-014-3731-5
S. Bannani, N. Christou, C. Guérin, A. Hamy, F. Sebag, M. Mathonnet, P. Guillot, C. Caillard, C. Blanchard, E. Mirallié, Effect of parathyroidectomy on quality of life and non-specific symptoms in normocalcaemic primary hyperparathyroidism. Br. J. Surg. 105, 223–229 (2018). https://doi.org/10.1002/bjs.10739
P. Cunha-Bezerra, R. Vieira, F. Amaral, H. Cartaxo, T. Lima, U. Montarroyos, F. Bandeira, Better performance of four-dimension computed tomography as a localization procedure in normocalcemic primary hyperparathyroidism. J. Med. Imaging Radiat. Oncol. 62, 493–498 (2018). https://doi.org/10.1111/1754-9485.12728
H. Mazeh, H. Chen, G. Leverson, R.S. Sippel, Creation of a “Wisconsin index” nomogram to predict the likelihood of additional hyperfunctioning parathyroid glands during parathyroidectomy. Ann. Surg. 257, 138–141 (2013). https://doi.org/10.1097/SLA.0b013e31825ffbe1
E. Trébouet, S. Bannani, M. Wargny, C. Leux, C. Caillard, F. Kraeber-Bodéré, K. Renaudin, L. Chaillous, É. Mirallié, C. Ansquer, Mild sporadic primary hyperparathyroidism: high rate of multiglandular disease is associated with lower surgical cure rate. Langenbeck’s Arch. Surg. 404, 431–438 (2019). https://doi.org/10.1007/s00423-019-01782-1
T.K. Pandian, C.C. Lubitz, S.H. Bird, L.E. Kuo, A.E. Stephen, Normocalcemic hyperparathyroidism: a collaborative endocrine surgery quality improvement program analysis. Surgery 167, 168–172 (2020). https://doi.org/10.1016/j.surg.2019.06.043
I. Bossert, S. Chytiris, M. Hodolic, L. Croce, L. Mansi, L. Chiovato, G. Mariani, G. Trifirò, PETC/CT with 18 F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism. J. Endocrinol. Invest. 42, 419–426 (2019). https://doi.org/10.1007/s40618-018-0931-z
D.M. Carneiro, C.C. Solorzano, M.C. Nader, M. Ramirez, G.L. Irvin, 3rd: Comparison of intraoperative iPTH assay (QPTH) criteria in guiding parathyroidectomy: which criterion is the most accurate? Surgery 134, 973–981 (2003). https://doi.org/10.1016/j.surg.2003.06.001
T.J. Wade, T.W.F. Yen, A.L. Amin, T.S. Wang, Surgical management of normocalcemic primary hyperparathyroidism. World J. Surg. 36, 761–766 (2012). https://doi.org/10.1007/s00268-012-1438-y
M.D. Walker, S.J. Silverberg, Primary hyperparathyroidism. Nat. Rev. Endocrinol. 14, 115–125 (2018). https://doi.org/10.1038/nrendo.2017.104
B. Farford, R.J. Presutti, T.J. Moraghan, Nonsurgical management of primary hyperparathyroidism. Mayo Clin. Proc. 82, 351–355 (2007). https://doi.org/10.4065/82.3.351
M.T. Drake, B.L. Clarke, S. Khosla, Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin. Proc. 83, 1032–1045 (2008). https://doi.org/10.4065/83.9.1032
A.A. Khan, J.P. Bilezikian, A.W.C. Kung, M.M. Ahmed, S.J. Dubois, A.Y.Y. Ho, D. Schussheim, M.R. Rubin, A.M. Shaikh, S.J. Silverberg, T.I. Standish, Z. Syed, Z.A. Syed, Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89, 3319–3325 (2004). https://doi.org/10.1210/jc.2003-030908
R. Cesareo, E. Di Stasio, F. Vescini, G. Campagna, R. Cianni, V. Pasqualini, F. Romitelli, F. Grimaldi, S. Manfrini, A. Palermo, Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos. Int. 26, 1295–1302 (2015). https://doi.org/10.1007/s00198-014-3000-2
G. Tsvetov, D. Hirsch, I. Shimon, C. Benbassat, H. Masri-Iraqi, A. Gorshtein, D. Herzberg, T. Shochat, I. Shraga-Slutzky, T. Diker-Cohen, Thiazide treatment in primary hyperparathyroidism-a new indication for an old medication? J. Clin. Endocrinol. Metab. 102, 1270–1276 (2017). https://doi.org/10.1210/jc.2016-2481
S. Brardi, G. Cevenini, T. Verdacchi, G. Romano, R. Ponchietti, Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. Arch. Ital. di Urol. Androl. 87, 66–71 (2015). https://doi.org/10.4081/aiua.2015.1.66
Author contributions
Conceptualization, J.L.M.N. and M.M.A.; literature review and writing—original draft preparation, J.L.M.N., M.S.N. and I.H.M.; writing—review and editing, J.L.M.N., M.S.N., I.H.M. and M.M.A.; supervision, J.L.M.N. and M.M.A. All authors have read and agreed to the published version of the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Muñoz de Nova, J.L., Sampedro-Nuñez, M., Huguet-Moreno, I. et al. A practical approach to normocalcemic primary hyperparathyroidism. Endocrine 74, 235–244 (2021). https://doi.org/10.1007/s12020-021-02845-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-021-02845-4